引用本文： 胡大一. 用循證醫(yī)學(xué)指導(dǎo)心血管疾病的防治. 中國(guó)循證醫(yī)學(xué)雜志, 2004, 04(5): 285-287. doi: 復(fù)制
| 1. | ［1］The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction[J]. N Engl J Med, 1989; 321:406-412. |
| 2. | ［2］Furberg CD, Bruce M, Jeffrey V. Nifedipine Dose-Related Increase in Mortality in Patients With Coronary Heart Disease[J].Circulation, 1995; 92:1 326-1 331. |
| 3. | ［3］The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial ( ALLHATLLT) [J]. JAMA, 2002; 288:2 998-3 007. |
| 4. | ［4］Sever PS, DahlofB, Poulter NB, Wedel H, Beevers G,Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised trial [ J ]. Lancet,2003; 361:1149-1158. |
- 1. ［1］The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction[J]. N Engl J Med, 1989; 321:406-412.
- 2. ［2］Furberg CD, Bruce M, Jeffrey V. Nifedipine Dose-Related Increase in Mortality in Patients With Coronary Heart Disease[J].Circulation, 1995; 92:1 326-1 331.
- 3. ［3］The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial ( ALLHATLLT) [J]. JAMA, 2002; 288:2 998-3 007.
- 4. ［4］Sever PS, DahlofB, Poulter NB, Wedel H, Beevers G,Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised trial [ J ]. Lancet,2003; 361:1149-1158.